Biopharmaceutical Optimisation of β-Cyclodextrin Inclusion Compounds
Summary To improve the biopharmaceutical performance of the nonsteroidal anti-inflammatory drug piroxicam, inclusion compounds with β-cyclodextrin carrier have been prepared and studied for a wide range of chemical, physical and pharmaceutical properties. Three bulk products were obtained, 2 by a pr...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Acerbi, D. [verfasserIn] Bovis, G. [verfasserIn] Carli, F. [verfasserIn] Pasini, M. [verfasserIn] Pavesi, L. [verfasserIn] Peveri, T. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1990 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Clinical drug investigation - Berlin [u.a.] : Springer, 1989, 2(1990), Suppl 4 vom: Jan., Seite 29-36 |
|---|---|
| Übergeordnetes Werk: |
volume:2 ; year:1990 ; number:Suppl 4 ; month:01 ; pages:29-36 |
| Links: |
|---|
| DOI / URN: |
10.1007/BF03258224 |
|---|
| Katalog-ID: |
SPR032994958 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR032994958 | ||
| 003 | DE-627 | ||
| 005 | 20230519200745.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s1990 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/BF03258224 |2 doi | |
| 035 | |a (DE-627)SPR032994958 | ||
| 035 | |a (SPR)BF03258224-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Acerbi, D. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Biopharmaceutical Optimisation of β-Cyclodextrin Inclusion Compounds |
| 264 | 1 | |c 1990 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Summary To improve the biopharmaceutical performance of the nonsteroidal anti-inflammatory drug piroxicam, inclusion compounds with β-cyclodextrin carrier have been prepared and studied for a wide range of chemical, physical and pharmaceutical properties. Three bulk products were obtained, 2 by a process of freeze-drying (preparation A/1 and preparation A/2) and changing process parameters, and 1 by spray-drying (preparation B). The objective was to obtain tablets which provide a rapid-release dosage form of piroxicam. Studies were conducted in vitro and in humans and compared tablets of the inclusion complex of piroxicam and β-cyclodextrin with marketed oral and parenteral dosage forms of piroxicam. Significant differences were found in plasma levels, maximum plasma concentration ($ C_{max} $) and area under the plasma concentration-time curve (AUC), confirming that biopharmaceutical optimisation of the complexes can be achieved, leading to an overall pattern of absorption which is better than those presented by standard, non-complexed formulations of piroxicam (capsules, and ampoules for intramuscular use). Evidence for a correlation between the 2 main physicopharmaceutical variables (solubilisation kinetics of the complex and dissolution rate of the tablet) and biopharmaceutical performances support the development of the product. | ||
| 650 | 4 | |a Dissolution Rate |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Inclusion Complex |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Piroxicam |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Water Contact Angle |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Physical Mixture |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Bovis, G. |e verfasserin |4 aut | |
| 700 | 1 | |a Carli, F. |e verfasserin |4 aut | |
| 700 | 1 | |a Pasini, M. |e verfasserin |4 aut | |
| 700 | 1 | |a Pavesi, L. |e verfasserin |4 aut | |
| 700 | 1 | |a Peveri, T. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical drug investigation |d Berlin [u.a.] : Springer, 1989 |g 2(1990), Suppl 4 vom: Jan., Seite 29-36 |w (DE-627)327645083 |w (DE-600)2043793-6 |x 1179-1918 |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:1990 |g number:Suppl 4 |g month:01 |g pages:29-36 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/BF03258224 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2190 | ||
| 936 | b | k | |a 44.40 |q ASE |
| 951 | |a AR | ||
| 952 | |d 2 |j 1990 |e Suppl 4 |c 01 |h 29-36 | ||
| author_variant |
d a da g b gb f c fc m p mp l p lp t p tp |
|---|---|
| matchkey_str |
article:11791918:1990----::ipamcuiaotmstooccoetii |
| hierarchy_sort_str |
1990 |
| bklnumber |
44.40 |
| publishDate |
1990 |
| allfields |
10.1007/BF03258224 doi (DE-627)SPR032994958 (SPR)BF03258224-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Acerbi, D. verfasserin aut Biopharmaceutical Optimisation of β-Cyclodextrin Inclusion Compounds 1990 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary To improve the biopharmaceutical performance of the nonsteroidal anti-inflammatory drug piroxicam, inclusion compounds with β-cyclodextrin carrier have been prepared and studied for a wide range of chemical, physical and pharmaceutical properties. Three bulk products were obtained, 2 by a process of freeze-drying (preparation A/1 and preparation A/2) and changing process parameters, and 1 by spray-drying (preparation B). The objective was to obtain tablets which provide a rapid-release dosage form of piroxicam. Studies were conducted in vitro and in humans and compared tablets of the inclusion complex of piroxicam and β-cyclodextrin with marketed oral and parenteral dosage forms of piroxicam. Significant differences were found in plasma levels, maximum plasma concentration ($ C_{max} $) and area under the plasma concentration-time curve (AUC), confirming that biopharmaceutical optimisation of the complexes can be achieved, leading to an overall pattern of absorption which is better than those presented by standard, non-complexed formulations of piroxicam (capsules, and ampoules for intramuscular use). Evidence for a correlation between the 2 main physicopharmaceutical variables (solubilisation kinetics of the complex and dissolution rate of the tablet) and biopharmaceutical performances support the development of the product. Dissolution Rate (dpeaa)DE-He213 Inclusion Complex (dpeaa)DE-He213 Piroxicam (dpeaa)DE-He213 Water Contact Angle (dpeaa)DE-He213 Physical Mixture (dpeaa)DE-He213 Bovis, G. verfasserin aut Carli, F. verfasserin aut Pasini, M. verfasserin aut Pavesi, L. verfasserin aut Peveri, T. verfasserin aut Enthalten in Clinical drug investigation Berlin [u.a.] : Springer, 1989 2(1990), Suppl 4 vom: Jan., Seite 29-36 (DE-627)327645083 (DE-600)2043793-6 1179-1918 nnns volume:2 year:1990 number:Suppl 4 month:01 pages:29-36 https://dx.doi.org/10.1007/BF03258224 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 2 1990 Suppl 4 01 29-36 |
| spelling |
10.1007/BF03258224 doi (DE-627)SPR032994958 (SPR)BF03258224-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Acerbi, D. verfasserin aut Biopharmaceutical Optimisation of β-Cyclodextrin Inclusion Compounds 1990 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary To improve the biopharmaceutical performance of the nonsteroidal anti-inflammatory drug piroxicam, inclusion compounds with β-cyclodextrin carrier have been prepared and studied for a wide range of chemical, physical and pharmaceutical properties. Three bulk products were obtained, 2 by a process of freeze-drying (preparation A/1 and preparation A/2) and changing process parameters, and 1 by spray-drying (preparation B). The objective was to obtain tablets which provide a rapid-release dosage form of piroxicam. Studies were conducted in vitro and in humans and compared tablets of the inclusion complex of piroxicam and β-cyclodextrin with marketed oral and parenteral dosage forms of piroxicam. Significant differences were found in plasma levels, maximum plasma concentration ($ C_{max} $) and area under the plasma concentration-time curve (AUC), confirming that biopharmaceutical optimisation of the complexes can be achieved, leading to an overall pattern of absorption which is better than those presented by standard, non-complexed formulations of piroxicam (capsules, and ampoules for intramuscular use). Evidence for a correlation between the 2 main physicopharmaceutical variables (solubilisation kinetics of the complex and dissolution rate of the tablet) and biopharmaceutical performances support the development of the product. Dissolution Rate (dpeaa)DE-He213 Inclusion Complex (dpeaa)DE-He213 Piroxicam (dpeaa)DE-He213 Water Contact Angle (dpeaa)DE-He213 Physical Mixture (dpeaa)DE-He213 Bovis, G. verfasserin aut Carli, F. verfasserin aut Pasini, M. verfasserin aut Pavesi, L. verfasserin aut Peveri, T. verfasserin aut Enthalten in Clinical drug investigation Berlin [u.a.] : Springer, 1989 2(1990), Suppl 4 vom: Jan., Seite 29-36 (DE-627)327645083 (DE-600)2043793-6 1179-1918 nnns volume:2 year:1990 number:Suppl 4 month:01 pages:29-36 https://dx.doi.org/10.1007/BF03258224 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 2 1990 Suppl 4 01 29-36 |
| allfields_unstemmed |
10.1007/BF03258224 doi (DE-627)SPR032994958 (SPR)BF03258224-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Acerbi, D. verfasserin aut Biopharmaceutical Optimisation of β-Cyclodextrin Inclusion Compounds 1990 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary To improve the biopharmaceutical performance of the nonsteroidal anti-inflammatory drug piroxicam, inclusion compounds with β-cyclodextrin carrier have been prepared and studied for a wide range of chemical, physical and pharmaceutical properties. Three bulk products were obtained, 2 by a process of freeze-drying (preparation A/1 and preparation A/2) and changing process parameters, and 1 by spray-drying (preparation B). The objective was to obtain tablets which provide a rapid-release dosage form of piroxicam. Studies were conducted in vitro and in humans and compared tablets of the inclusion complex of piroxicam and β-cyclodextrin with marketed oral and parenteral dosage forms of piroxicam. Significant differences were found in plasma levels, maximum plasma concentration ($ C_{max} $) and area under the plasma concentration-time curve (AUC), confirming that biopharmaceutical optimisation of the complexes can be achieved, leading to an overall pattern of absorption which is better than those presented by standard, non-complexed formulations of piroxicam (capsules, and ampoules for intramuscular use). Evidence for a correlation between the 2 main physicopharmaceutical variables (solubilisation kinetics of the complex and dissolution rate of the tablet) and biopharmaceutical performances support the development of the product. Dissolution Rate (dpeaa)DE-He213 Inclusion Complex (dpeaa)DE-He213 Piroxicam (dpeaa)DE-He213 Water Contact Angle (dpeaa)DE-He213 Physical Mixture (dpeaa)DE-He213 Bovis, G. verfasserin aut Carli, F. verfasserin aut Pasini, M. verfasserin aut Pavesi, L. verfasserin aut Peveri, T. verfasserin aut Enthalten in Clinical drug investigation Berlin [u.a.] : Springer, 1989 2(1990), Suppl 4 vom: Jan., Seite 29-36 (DE-627)327645083 (DE-600)2043793-6 1179-1918 nnns volume:2 year:1990 number:Suppl 4 month:01 pages:29-36 https://dx.doi.org/10.1007/BF03258224 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 2 1990 Suppl 4 01 29-36 |
| allfieldsGer |
10.1007/BF03258224 doi (DE-627)SPR032994958 (SPR)BF03258224-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Acerbi, D. verfasserin aut Biopharmaceutical Optimisation of β-Cyclodextrin Inclusion Compounds 1990 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary To improve the biopharmaceutical performance of the nonsteroidal anti-inflammatory drug piroxicam, inclusion compounds with β-cyclodextrin carrier have been prepared and studied for a wide range of chemical, physical and pharmaceutical properties. Three bulk products were obtained, 2 by a process of freeze-drying (preparation A/1 and preparation A/2) and changing process parameters, and 1 by spray-drying (preparation B). The objective was to obtain tablets which provide a rapid-release dosage form of piroxicam. Studies were conducted in vitro and in humans and compared tablets of the inclusion complex of piroxicam and β-cyclodextrin with marketed oral and parenteral dosage forms of piroxicam. Significant differences were found in plasma levels, maximum plasma concentration ($ C_{max} $) and area under the plasma concentration-time curve (AUC), confirming that biopharmaceutical optimisation of the complexes can be achieved, leading to an overall pattern of absorption which is better than those presented by standard, non-complexed formulations of piroxicam (capsules, and ampoules for intramuscular use). Evidence for a correlation between the 2 main physicopharmaceutical variables (solubilisation kinetics of the complex and dissolution rate of the tablet) and biopharmaceutical performances support the development of the product. Dissolution Rate (dpeaa)DE-He213 Inclusion Complex (dpeaa)DE-He213 Piroxicam (dpeaa)DE-He213 Water Contact Angle (dpeaa)DE-He213 Physical Mixture (dpeaa)DE-He213 Bovis, G. verfasserin aut Carli, F. verfasserin aut Pasini, M. verfasserin aut Pavesi, L. verfasserin aut Peveri, T. verfasserin aut Enthalten in Clinical drug investigation Berlin [u.a.] : Springer, 1989 2(1990), Suppl 4 vom: Jan., Seite 29-36 (DE-627)327645083 (DE-600)2043793-6 1179-1918 nnns volume:2 year:1990 number:Suppl 4 month:01 pages:29-36 https://dx.doi.org/10.1007/BF03258224 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 2 1990 Suppl 4 01 29-36 |
| allfieldsSound |
10.1007/BF03258224 doi (DE-627)SPR032994958 (SPR)BF03258224-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Acerbi, D. verfasserin aut Biopharmaceutical Optimisation of β-Cyclodextrin Inclusion Compounds 1990 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary To improve the biopharmaceutical performance of the nonsteroidal anti-inflammatory drug piroxicam, inclusion compounds with β-cyclodextrin carrier have been prepared and studied for a wide range of chemical, physical and pharmaceutical properties. Three bulk products were obtained, 2 by a process of freeze-drying (preparation A/1 and preparation A/2) and changing process parameters, and 1 by spray-drying (preparation B). The objective was to obtain tablets which provide a rapid-release dosage form of piroxicam. Studies were conducted in vitro and in humans and compared tablets of the inclusion complex of piroxicam and β-cyclodextrin with marketed oral and parenteral dosage forms of piroxicam. Significant differences were found in plasma levels, maximum plasma concentration ($ C_{max} $) and area under the plasma concentration-time curve (AUC), confirming that biopharmaceutical optimisation of the complexes can be achieved, leading to an overall pattern of absorption which is better than those presented by standard, non-complexed formulations of piroxicam (capsules, and ampoules for intramuscular use). Evidence for a correlation between the 2 main physicopharmaceutical variables (solubilisation kinetics of the complex and dissolution rate of the tablet) and biopharmaceutical performances support the development of the product. Dissolution Rate (dpeaa)DE-He213 Inclusion Complex (dpeaa)DE-He213 Piroxicam (dpeaa)DE-He213 Water Contact Angle (dpeaa)DE-He213 Physical Mixture (dpeaa)DE-He213 Bovis, G. verfasserin aut Carli, F. verfasserin aut Pasini, M. verfasserin aut Pavesi, L. verfasserin aut Peveri, T. verfasserin aut Enthalten in Clinical drug investigation Berlin [u.a.] : Springer, 1989 2(1990), Suppl 4 vom: Jan., Seite 29-36 (DE-627)327645083 (DE-600)2043793-6 1179-1918 nnns volume:2 year:1990 number:Suppl 4 month:01 pages:29-36 https://dx.doi.org/10.1007/BF03258224 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 2 1990 Suppl 4 01 29-36 |
| language |
English |
| source |
Enthalten in Clinical drug investigation 2(1990), Suppl 4 vom: Jan., Seite 29-36 volume:2 year:1990 number:Suppl 4 month:01 pages:29-36 |
| sourceStr |
Enthalten in Clinical drug investigation 2(1990), Suppl 4 vom: Jan., Seite 29-36 volume:2 year:1990 number:Suppl 4 month:01 pages:29-36 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Dissolution Rate Inclusion Complex Piroxicam Water Contact Angle Physical Mixture |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Clinical drug investigation |
| authorswithroles_txt_mv |
Acerbi, D. @@aut@@ Bovis, G. @@aut@@ Carli, F. @@aut@@ Pasini, M. @@aut@@ Pavesi, L. @@aut@@ Peveri, T. @@aut@@ |
| publishDateDaySort_date |
1990-01-01T00:00:00Z |
| hierarchy_top_id |
327645083 |
| dewey-sort |
3610 |
| id |
SPR032994958 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR032994958</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519200745.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1990 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/BF03258224</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR032994958</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)BF03258224-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Acerbi, D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Biopharmaceutical Optimisation of β-Cyclodextrin Inclusion Compounds</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1990</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary To improve the biopharmaceutical performance of the nonsteroidal anti-inflammatory drug piroxicam, inclusion compounds with β-cyclodextrin carrier have been prepared and studied for a wide range of chemical, physical and pharmaceutical properties. Three bulk products were obtained, 2 by a process of freeze-drying (preparation A/1 and preparation A/2) and changing process parameters, and 1 by spray-drying (preparation B). The objective was to obtain tablets which provide a rapid-release dosage form of piroxicam. Studies were conducted in vitro and in humans and compared tablets of the inclusion complex of piroxicam and β-cyclodextrin with marketed oral and parenteral dosage forms of piroxicam. Significant differences were found in plasma levels, maximum plasma concentration ($ C_{max} $) and area under the plasma concentration-time curve (AUC), confirming that biopharmaceutical optimisation of the complexes can be achieved, leading to an overall pattern of absorption which is better than those presented by standard, non-complexed formulations of piroxicam (capsules, and ampoules for intramuscular use). Evidence for a correlation between the 2 main physicopharmaceutical variables (solubilisation kinetics of the complex and dissolution rate of the tablet) and biopharmaceutical performances support the development of the product.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Dissolution Rate</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Inclusion Complex</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Piroxicam</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Water Contact Angle</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Physical Mixture</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bovis, G.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Carli, F.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pasini, M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pavesi, L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Peveri, T.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Clinical drug investigation</subfield><subfield code="d">Berlin [u.a.] : Springer, 1989</subfield><subfield code="g">2(1990), Suppl 4 vom: Jan., Seite 29-36</subfield><subfield code="w">(DE-627)327645083</subfield><subfield code="w">(DE-600)2043793-6</subfield><subfield code="x">1179-1918</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2</subfield><subfield code="g">year:1990</subfield><subfield code="g">number:Suppl 4</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:29-36</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/BF03258224</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">2</subfield><subfield code="j">1990</subfield><subfield code="e">Suppl 4</subfield><subfield code="c">01</subfield><subfield code="h">29-36</subfield></datafield></record></collection>
|
| author |
Acerbi, D. |
| spellingShingle |
Acerbi, D. ddc 610 bkl 44.40 misc Dissolution Rate misc Inclusion Complex misc Piroxicam misc Water Contact Angle misc Physical Mixture Biopharmaceutical Optimisation of β-Cyclodextrin Inclusion Compounds |
| authorStr |
Acerbi, D. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)327645083 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1179-1918 |
| topic_title |
610 ASE 44.40 bkl Biopharmaceutical Optimisation of β-Cyclodextrin Inclusion Compounds Dissolution Rate (dpeaa)DE-He213 Inclusion Complex (dpeaa)DE-He213 Piroxicam (dpeaa)DE-He213 Water Contact Angle (dpeaa)DE-He213 Physical Mixture (dpeaa)DE-He213 |
| topic |
ddc 610 bkl 44.40 misc Dissolution Rate misc Inclusion Complex misc Piroxicam misc Water Contact Angle misc Physical Mixture |
| topic_unstemmed |
ddc 610 bkl 44.40 misc Dissolution Rate misc Inclusion Complex misc Piroxicam misc Water Contact Angle misc Physical Mixture |
| topic_browse |
ddc 610 bkl 44.40 misc Dissolution Rate misc Inclusion Complex misc Piroxicam misc Water Contact Angle misc Physical Mixture |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Clinical drug investigation |
| hierarchy_parent_id |
327645083 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Clinical drug investigation |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)327645083 (DE-600)2043793-6 |
| title |
Biopharmaceutical Optimisation of β-Cyclodextrin Inclusion Compounds |
| ctrlnum |
(DE-627)SPR032994958 (SPR)BF03258224-e |
| title_full |
Biopharmaceutical Optimisation of β-Cyclodextrin Inclusion Compounds |
| author_sort |
Acerbi, D. |
| journal |
Clinical drug investigation |
| journalStr |
Clinical drug investigation |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
1990 |
| contenttype_str_mv |
txt |
| container_start_page |
29 |
| author_browse |
Acerbi, D. Bovis, G. Carli, F. Pasini, M. Pavesi, L. Peveri, T. |
| container_volume |
2 |
| class |
610 ASE 44.40 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Acerbi, D. |
| doi_str_mv |
10.1007/BF03258224 |
| dewey-full |
610 |
| author2-role |
verfasserin |
| title_sort |
biopharmaceutical optimisation of β-cyclodextrin inclusion compounds |
| title_auth |
Biopharmaceutical Optimisation of β-Cyclodextrin Inclusion Compounds |
| abstract |
Summary To improve the biopharmaceutical performance of the nonsteroidal anti-inflammatory drug piroxicam, inclusion compounds with β-cyclodextrin carrier have been prepared and studied for a wide range of chemical, physical and pharmaceutical properties. Three bulk products were obtained, 2 by a process of freeze-drying (preparation A/1 and preparation A/2) and changing process parameters, and 1 by spray-drying (preparation B). The objective was to obtain tablets which provide a rapid-release dosage form of piroxicam. Studies were conducted in vitro and in humans and compared tablets of the inclusion complex of piroxicam and β-cyclodextrin with marketed oral and parenteral dosage forms of piroxicam. Significant differences were found in plasma levels, maximum plasma concentration ($ C_{max} $) and area under the plasma concentration-time curve (AUC), confirming that biopharmaceutical optimisation of the complexes can be achieved, leading to an overall pattern of absorption which is better than those presented by standard, non-complexed formulations of piroxicam (capsules, and ampoules for intramuscular use). Evidence for a correlation between the 2 main physicopharmaceutical variables (solubilisation kinetics of the complex and dissolution rate of the tablet) and biopharmaceutical performances support the development of the product. |
| abstractGer |
Summary To improve the biopharmaceutical performance of the nonsteroidal anti-inflammatory drug piroxicam, inclusion compounds with β-cyclodextrin carrier have been prepared and studied for a wide range of chemical, physical and pharmaceutical properties. Three bulk products were obtained, 2 by a process of freeze-drying (preparation A/1 and preparation A/2) and changing process parameters, and 1 by spray-drying (preparation B). The objective was to obtain tablets which provide a rapid-release dosage form of piroxicam. Studies were conducted in vitro and in humans and compared tablets of the inclusion complex of piroxicam and β-cyclodextrin with marketed oral and parenteral dosage forms of piroxicam. Significant differences were found in plasma levels, maximum plasma concentration ($ C_{max} $) and area under the plasma concentration-time curve (AUC), confirming that biopharmaceutical optimisation of the complexes can be achieved, leading to an overall pattern of absorption which is better than those presented by standard, non-complexed formulations of piroxicam (capsules, and ampoules for intramuscular use). Evidence for a correlation between the 2 main physicopharmaceutical variables (solubilisation kinetics of the complex and dissolution rate of the tablet) and biopharmaceutical performances support the development of the product. |
| abstract_unstemmed |
Summary To improve the biopharmaceutical performance of the nonsteroidal anti-inflammatory drug piroxicam, inclusion compounds with β-cyclodextrin carrier have been prepared and studied for a wide range of chemical, physical and pharmaceutical properties. Three bulk products were obtained, 2 by a process of freeze-drying (preparation A/1 and preparation A/2) and changing process parameters, and 1 by spray-drying (preparation B). The objective was to obtain tablets which provide a rapid-release dosage form of piroxicam. Studies were conducted in vitro and in humans and compared tablets of the inclusion complex of piroxicam and β-cyclodextrin with marketed oral and parenteral dosage forms of piroxicam. Significant differences were found in plasma levels, maximum plasma concentration ($ C_{max} $) and area under the plasma concentration-time curve (AUC), confirming that biopharmaceutical optimisation of the complexes can be achieved, leading to an overall pattern of absorption which is better than those presented by standard, non-complexed formulations of piroxicam (capsules, and ampoules for intramuscular use). Evidence for a correlation between the 2 main physicopharmaceutical variables (solubilisation kinetics of the complex and dissolution rate of the tablet) and biopharmaceutical performances support the development of the product. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 |
| container_issue |
Suppl 4 |
| title_short |
Biopharmaceutical Optimisation of β-Cyclodextrin Inclusion Compounds |
| url |
https://dx.doi.org/10.1007/BF03258224 |
| remote_bool |
true |
| author2 |
Bovis, G. Carli, F. Pasini, M. Pavesi, L. Peveri, T. |
| author2Str |
Bovis, G. Carli, F. Pasini, M. Pavesi, L. Peveri, T. |
| ppnlink |
327645083 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/BF03258224 |
| up_date |
2024-07-03T15:56:26.111Z |
| _version_ |
1803573983823527936 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR032994958</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519200745.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1990 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/BF03258224</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR032994958</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)BF03258224-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Acerbi, D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Biopharmaceutical Optimisation of β-Cyclodextrin Inclusion Compounds</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1990</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary To improve the biopharmaceutical performance of the nonsteroidal anti-inflammatory drug piroxicam, inclusion compounds with β-cyclodextrin carrier have been prepared and studied for a wide range of chemical, physical and pharmaceutical properties. Three bulk products were obtained, 2 by a process of freeze-drying (preparation A/1 and preparation A/2) and changing process parameters, and 1 by spray-drying (preparation B). The objective was to obtain tablets which provide a rapid-release dosage form of piroxicam. Studies were conducted in vitro and in humans and compared tablets of the inclusion complex of piroxicam and β-cyclodextrin with marketed oral and parenteral dosage forms of piroxicam. Significant differences were found in plasma levels, maximum plasma concentration ($ C_{max} $) and area under the plasma concentration-time curve (AUC), confirming that biopharmaceutical optimisation of the complexes can be achieved, leading to an overall pattern of absorption which is better than those presented by standard, non-complexed formulations of piroxicam (capsules, and ampoules for intramuscular use). Evidence for a correlation between the 2 main physicopharmaceutical variables (solubilisation kinetics of the complex and dissolution rate of the tablet) and biopharmaceutical performances support the development of the product.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Dissolution Rate</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Inclusion Complex</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Piroxicam</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Water Contact Angle</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Physical Mixture</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bovis, G.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Carli, F.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pasini, M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pavesi, L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Peveri, T.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Clinical drug investigation</subfield><subfield code="d">Berlin [u.a.] : Springer, 1989</subfield><subfield code="g">2(1990), Suppl 4 vom: Jan., Seite 29-36</subfield><subfield code="w">(DE-627)327645083</subfield><subfield code="w">(DE-600)2043793-6</subfield><subfield code="x">1179-1918</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2</subfield><subfield code="g">year:1990</subfield><subfield code="g">number:Suppl 4</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:29-36</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/BF03258224</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">2</subfield><subfield code="j">1990</subfield><subfield code="e">Suppl 4</subfield><subfield code="c">01</subfield><subfield code="h">29-36</subfield></datafield></record></collection>
|
| score |
7.3995905 |